Welcome to BioSeeker Group!

Analytical Tool - Angiogenesis in Oncology

Additional Information

Published Date Feb 21, 2012
Format PDF & Software Application
Publisher BioSeeker Group

Availability: In stock

€3,100.00

Quick Overview

The ultimate tool for serious players who would like to understand the current competitive field in cancer drug development among anti-angiogenic and vascular targeting agents.
Request free sample pages from Analytical Tool - Angiogenesis in Oncology

"Analytical Tool - Angiogenesis in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in anti-angiogenic drug development for the treatment of cancer. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. This tool provides you with an immense amount of information structured and analyzed to assist you in your work. It is designed to assist you in finding right partners, optimizing your licensing deals, wisely choosing which projects give you the best competitive advantage, and assuring you that your decisions have been based on the most accurate, validated and precise facts available.

Included in this advantageous package are two products already appreciated by many of our customers:


The Package Includes

  • A progress analysis on current and emerging drugs
  • Information on most companies active in anti-angiogenic R&D in oncology
  • Information on key industry related anti-angiogenic drug projects in oncology
  • Data from most important clinical trials
  • Information on early developmental stage projects
  • Possibility of performing advanced searches suited to your individual needs

This Tool will Assist You in:

  • Tracking cutting edge companies, therapies and new technologies
  • Rapid identification of partners & competitors
  • Laying down a comprehensive framework for further analysis of the field
  • Producing presentations surrounding the development of anti-angiogenic drugs in oncology
  • Identifying emerging anti-angiogenic cancer products & key areas of pharmaceutical R&D

*This software application is a searchable database reflects the most recent advances in the field of anti-angiogenic drug development in cancer, in order to help you perform your own analysis, go back to the source data for in-depth information, and present the research and development in tables and graphs suited for your own specific purposes. A significant advantage with BioSeeker’s software applications is that they provide you with well-structured information. Each pipeline drug/project has been carefully defined and classified in categories and subcategories. The main categories include therapy type, effect, mechanism of action (molecular target), indication, stage of development etc. These categories are further organized and classified in sub-categories. In comparison with other available databases, BioSeeker’s software applications give better overview, specific search capabilities and great dynamic reports.

Request free sample pages from Analytical Tool - Angiogenesis in Oncology

Other selected research from the 'Analytical Tool' category:


Analytical Tool - Breast Cancer
The ultimate tool for serious players who would like to understand the current competitive field in breast cancer drug development. Learn More


Analytical Tool - Cancer Therapeutic Antibodies
A unique tool for analyzing the vast amount of strategic possibilities that have emerged in cancer antibody R&D and business development. Learn More

Other selected research from the 'R&D' category:


Proteins in Oncology Drug Pipeline Update 2012
BioSeeker Group have identified 306 companies plus partners who are today developing 332 protein drugs in 570 developmental projects in cancer across 154 different targets. In addition, there are 2 suspended drugs and another 164 drugs where development has been ceased. Learn More


TSLP Signaling Pathway in Oncology Drug Pipeline Update 2012
BioSeeker Group have identified 151 companies plus partners who are today developing 163 TSLP pathway targeting drugs in 454 developmental projects in cancer across 110 different targets. In addition, there are 2 suspended drugs and another 75 drugs where development has been ceased. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Prostate Cancer, Apoptosis and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in Prostate Cancer and by the two mechanism/target/effect areas of Apoptosis and Cancer Vaccines. Learn More


Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
This report will excel your competitive awareness and decrease your decision making time in managing apoptotic drug development in cancer. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you. Learn More

Other selected research from the 'Line of Treatment' category:


Analytical Tool - Angiogenesis in Oncology
The ultimate tool for serious players who would like to understand the current competitive field in cancer drug development among anti-angiogenic and vascular targeting agents. Learn More


The World Antibacterial Treatments Market 2010-2024
Over 130 tables, charts, graphs, figures included. Our latest report examines the prospects for antibacterial treatments worldwide from 2009 to 2024, including detailed sales forecasts for leading products in that... Learn More